Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza (H5N1)Vaccine in Two-Dose Primed Healthy Adults: A Single Center, Non-Randomized Clinical Trial.
Phase of Trial: Phase I
Latest Information Update: 23 Apr 2013
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sinovac Biotech
- 16 May 2008 Production license from the State Food and Drug Administration (SFDA) for exclusive supply of Panflu to the national stockpiling program.
- 21 Apr 2008 The expected completion date for this trial is now 1 Mar 2008.
- 01 Oct 2007 Status change